Maze Therapeutics Inc（MAZE）の財務MAZEMaze Therapeutics Inc

Evaluating the bottom line, Maze Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -372.94%, while the net margin is -344.68%. These profitability ratios, combined with a Return on Equity (ROE) of -37.35%, provide a clear picture of how effectively MAZE converts its operational activities into shareholder value.

In the context of the broader market, MAZE competes directly with industry leaders such as OCUL and GPCR. With a market capitalization of $1.80B, it holds a leading position in the sector. When comparing efficiency, MAZE's gross margin of 100.00% stands against OCUL's 85.08% and GPCR's N/A. Such benchmarking helps identify whether Maze Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Maze Therapeutics has shown a gross margin of 100% in Q1 2026, indicating strong potential for profitability once revenue begins to flow. However, it has been operating at a net loss, with a net income of -24.2 million USD in Q1 2026.